One Year of Recombinant Human Growth Hormone Treatment in Adults with Prader-Willi Syndrome Improves Body Composition, Motor Skills and Brain Functional Activity in the Cerebellum
Casamitjana, Laia (Universitat Autònoma de Barcelona. Departament de Medicina)
Blanco Hinojo, Laura (Centro de Investigación Biomédica en Red de Salud Mental)
Giménez-Palop, Olga (Universitat Autònoma de Barcelona. Departament de Medicina)
Pujol Nuez, Jesús (Centro de Investigación Biomédica en Red de Salud Mental)
Martínez-Vilavella, Gerard (Hospital del Mar (Barcelona, Catalunya))
Esteba-Castillo, Susanna (Parc Hospitalari Martí i Julià)
Pareja, Rocío (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Freijo, Valentín (Universitat Autònoma de Barcelona. Departament de Medicina)
Vigil Giménez, Laura (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Deus Yela, Juan (Hospital del Mar (Barcelona, Catalunya))
Caixàs i Pedragós, Assumpta (Universitat Autònoma de Barcelona. Departament de Medicina)

Date:	2022
Abstract:	We compared body composition, biochemical parameters, motor function, and brain neural activation in 27 adults with Prader-Willi syndrome and growth-hormone deficiency versus age-and sex-matched controls and baseline versus posttreatment values of these parameters after one year of recombinant human growth hormone (rhGH) treatment. To study body composition, we analyzed percentage of fat mass, percentage of lean mass, and muscle-mass surrogate variables from dual X-ray absorptiometry. Biochemical parameters analyzed included IGF-I, glucose metabolism, and myokines (myostatin, irisin, and IL6). To explore muscle function, we used dynamometer-measured handgrip strength, the Timed Up and Go (TUG) test, and the Berg Balance Scale (BBS). To study brain activation, we acquired functional magnetic resonance images during three motor tasks of varying complexity. After one year of treatment, we observed an increase in lean mass and its surrogates, a decrease in fat mass, improvements in TUG test and BBS scores, and increased neural activation in certain cerebellar areas. The treatment did not significantly worsen glucose metabolism, and no side-effects were reported. Our findings support the benefits of rhGH treatment in adults with Prader-Willi syndrome and growth-hormone deficiency on body composition and suggest that it may also improve balance and brain neural activation.
Grants:	Instituto de Salud Carlos III PI-18/00734
Note:	Altres ajuts: Fundació Parc Taulí CIR2020/022
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Prader-Willi syndrome ; Growth hormone ; Hypotonia ; Motor function ; FMRI ; Myokines
Published in:	Journal of clinical medicine, Vol. 11 Núm. 7 (2022) , p. 1831, ISSN 2077-0383

DOI: 10.3390/jcm11071831
PMID: 35407437

14 p, 1.0 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles